Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Coronary Artery Disease: HELP
Articles from Washington
Based on 203 articles published since 2008
||||

These are the 203 published articles about Coronary Artery Disease that originated from Washington during 2008-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9
1 Guideline ACR Appropriateness Criteria 2017

Anonymous3940905 / Akers, Scott R / Panchal, Vandan / Ho, Vincent B / Beache, Garth M / Brown, Richard K J / Ghoshhajra, Brian B / Greenberg, S Bruce / Hsu, Joe Y / Kicska, Gregory A / Min, James K / Stillman, Arthur E / Stojanovska, Jadranka / Abbara, Suhny / Jacobs, Jill E. ·Principal Author, VA Medical Center, Philadelphia, Pennsylvania. Electronic address: akerssco@me.com. · Research Author, Internal Medicine Resident, Henry Ford Allegiance Health, Jackson, Michigan. · Panel Vice-Chair, Uniformed Services University of the Health Sciences, Bethesda, Maryland. · University of Louisville School of Medicine, Louisville, Kentucky. · University Hospital, Ann Arbor, Michigan. · Massachusetts General Hospital, Boston, Massachusetts. · Arkansas Children's Hospital, Little Rock, Arkansas. · Kaiser Permanente, Los Angeles, California. · University of Washington, Seattle, Washington. · Cedars Sinai Medical Center, Los Angeles, California; American College of Cardiology. · Emory University Hospital, Atlanta, Georgia. · University of Michigan Health System, Ann Arbor, Michigan. · Specialty Chair, UT Southwestern Medical Center, Dallas, Texas. · Panel Chair, New York University Medical Center, New York, New York. ·J Am Coll Radiol · Pubmed #28473096.

ABSTRACT: In patients with chronic chest pain in the setting of high probability of coronary artery disease (CAD), imaging has major and diverse roles. First, imaging is valuable in determining and documenting the presence, extent, and severity of myocardial ischemia, hibernation, scarring, and/or the presence, site, and severity of obstructive coronary lesions. Second, imaging findings are important in determining the course of management of patients with suspected chronic myocardial ischemia and better defining those patients best suited for medical therapy, angioplasty/stenting, or surgery. Third, imaging is also necessary to determine the long-term prognosis and likely benefit from various therapeutic options by evaluating ventricular function, diastolic relaxation, and end-systolic volume. Imaging studies are also required to demonstrate other abnormalities, such as congenital/acquired coronary anomalies and severe left ventricular hypertrophy, that can produce angina in the absence of symptomatic coronary obstructive disease due to atherosclerosis. Clinical risk assessment is necessary to determine the pretest probability of CAD. Multiple methods are available to categorize patients as low, medium, or high risk for developing CAD. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.

2 Editorial Epicardial adipose tissue-Truly at the heart of the coronaries? 2016

Phan, Binh An P / Bahrainy, Samira / Gill, Edward A. ·Division of Cardiology, Department of Medicine, San Francisco General Hospital, University of California, San Francisco, CA, USA. · Department of Emergency Medicine, VA Medical Center Puget Sound, Seattle, WA, USA; Harborview Medical Center, Seattle, WA, USA. · Division of Cardiology, Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA. Electronic address: eagill@u.washington.edu. ·J Clin Lipidol · Pubmed #27206933.

ABSTRACT: -- No abstract --

3 Editorial Spectral response in reversing coronary artery atherosclerosis with vitamin D supplementation in postmenopausal cynomolgus monkeys. 2016

Pru, James K. ·Center for Reproductive Biology, Washington State University, Pullman, WA. ·Menopause · Pubmed #27045701.

ABSTRACT: -- No abstract --

4 Editorial SCAI position statement concerning coverage policies for percutaneous coronary interventions based on the appropriate use criteria. 2016

Klein, Lloyd W / Blankenship, James C / Kolansky, Daniel M / Dean, Larry S / Naidu, Srihari S / Chambers, Charles E / Duffy, Peter L / Anonymous2810861. ·Rush Medical College, Chicago, IL. · Geisinger Medical Center, Danville, PA. · University of Pennsylvania School of Medicine, Philadelphia, PA. · University of Washington, Seattle, WA. · Winthrop University Hospital, Mineola, NY. · Hershey Medical Center, Hershey, PA. · FirstHealth of the Carolinas, Reid Heart Center, Pinehurst, NC. ·Catheter Cardiovasc Interv · Pubmed #26968441.

ABSTRACT: -- No abstract --

5 Editorial Heart-type fatty acid-binding protein (H-FABP) and coronary heart disease. 2016

Das, Undurti N. ·UND Life Sciences, 2020 S 360th St, # K-202, Federal Way, WA 98003, USA. Electronic address: undurti@lipidworld.com. ·Indian Heart J · Pubmed #26896261.

ABSTRACT: -- No abstract --

6 Editorial Insulin resistance and in-stent restenosis: could modulating insulin improve outcomes of percutaneous coronary intervention? 2015

Armstrong, Ehrin J / McCabe, James M. ·aVA Eastern Colorado Healthcare System, Division of Cardiology, Department of Medicine, University of Colorado School of Medicine, Denver, Colorado bDivision of Cardiology, Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA. ·Coron Artery Dis · Pubmed #25489860.

ABSTRACT: -- No abstract --

7 Editorial Coronary involvement in lupus patients: getting sharper pictures with advanced vascular imaging? 2014

Sun, Jie / Yuan, Chun. ·Department of Radiology, University of Washington, Seattle, Washington. · Department of Radiology, University of Washington, Seattle, Washington; Department of Bioengineering, University of Washington, Seattle, Washington. Electronic address: cyuan@uw.edu. ·JACC Cardiovasc Imaging · Pubmed #25124008.

ABSTRACT: -- No abstract --

8 Editorial β-blockers for secondary prevention in stable coronary artery disease: can observational studies provide valid answers? 2014

Floyd, James S. ·Cardiovascular Health Research Unit, University of Washington, Seattle, Washington, USA Department of Medicine, University of Washington, Seattle, Washington, USA. ·Heart · Pubmed #25060756.

ABSTRACT: -- No abstract --

9 Editorial Continuous positive airway pressure in cardiovascular medicine: the underlying physiology is frequently unknown. 2014

Agostoni, Piergiuseppe / Contini, Mauro / Sciomer, Susanna / Palermo, Pietro / Sisillo, Erminio. ·aCentro Cardiologico Monzino, IRCCS bDepartment of Clinical Sciences and Community Health, Cardiovascular Section, University of Milano, Milano, Italy cDivision of Pulmonary and Critical Care and Medicine, Department of Medicine, University of Washington, Seattle, Washington, USA dDepartment of Cardiovascular and Respiratory Sciences, 'La Sapienza' University, Rome, Italy. ·J Cardiovasc Med (Hagerstown) · Pubmed #24751479.

ABSTRACT: -- No abstract --

10 Review The State of the Absorb Bioresorbable Scaffold: Consensus From an Expert Panel. 2017

Bangalore, Sripal / Bezerra, Hiram G / Rizik, David G / Armstrong, Ehrin J / Samuels, Bruce / Naidu, Srihari S / Grines, Cindy L / Foster, Malcolm T / Choi, James W / Bertolet, Barry D / Shah, Atman P / Torguson, Rebecca / Avula, Surendra B / Wang, John C / Zidar, James P / Maksoud, Aziz / Kalyanasundaram, Arun / Yakubov, Steven J / Chehab, Bassem M / Spaedy, Anthony J / Potluri, Srini P / Caputo, Ronald P / Kondur, Ashok / Merritt, Robert F / Kaki, Amir / Quesada, Ramon / Parikh, Manish A / Toma, Catalin / Matar, Fadi / DeGregorio, Joseph / Nicholson, William / Batchelor, Wayne / Gollapudi, Raghava / Korngold, Ethan / Sumar, Riyaz / Chrysant, George S / Li, Jun / Gordon, John B / Dave, Rajesh M / Attizzani, Guilherme F / Stys, Tom P / Gigliotti, Osvaldo S / Murphy, Bruce E / Ellis, Stephen G / Waksman, Ron. ·Department of Medicine, New York University School of Medicine, New York, New York. Electronic address: sripalbangalore@gmail.com. · Department of Medicine, University Hospitals Cleveland Medical Center, Cleveland, Ohio. · Department of Medicine, HonorHealth and the HonorHealth Heart Group, Scottsdale, Arizona. · Department of Medicine, University of Colorado, Denver, Colorado. · Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California. · Department of Medicine, Westchester Medical Center, Valhalla, New York. · Department of Medicine, North Shore University Hospital, Manhasset, New York. · Department of Medicine, Tennova Healthcare, Knoxville, Tennessee. · Department of Medicine, Baylor Heart and Vascular Hospital, Dallas, Texas. · Department of Medicine, North Mississippi Medical Center, Tupelo, Mississippi. · Department of Medicine, University of Chicago, Chicago, Illinois. · Department of Medicine, MedStar Washington Hospital Center, Washington, DC. · Department of Medicine, Advocate Christ Hospital and Medical Center, Oak Lawn, Illinois. · Department of Medicine, MedStar Union Memorial Hospital, Baltimore, Maryland. · Department of Medicine, UNC/Rex Healthcare, Raleigh, North Carolina. · Department of Medicine, Cardiovascular Research Institute of Kansas, Kansas City, Kansas. · Department of Medicine, Seattle Heart and Vascular Institute, Seattle, Washington. · Department of Medicine, OhioHealth, Columbus, Ohio. · Department of Medicine, University of Kansas, Kansas City, Kansas. · Department of Medicine, Missouri Heart Center, Columbia, Missouri. · Department of Medicine, The Heart Hospital Baylor Plano, Plano, Texas. · Department of Medicine, St. Joseph's/Trinity Hospital, Syracuse, New York. · Department of Medicine, DMC Heart Hospital/Wayne State University, Detroit, Michigan. · Department of Medicine, Mercy Hospital and Clinic, Springfield, Missouri. · Department of Medicine, Heart & Vascular Institute, Detroit, Michigan. · Department of Medicine, Miami Cardiac & Vascular Institute, Baptist Health, Miami, Florida. · Department of Medicine, Columbia University Medical Center, New York, New York. · Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. · Department of Medicine, University of South Florida, Tampa, Florida. · Department of Medicine, Englewood Hospital and Medical Center, Englewood, New Jersey. · Department of Medicine, York Hospital, York, Pennsylvania. · Department of Medicine, Tallahassee Memorial Hospital/Florida State University, Tallahassee, Florida. · Department of Medicine, San Diego Cardiac Center, San Diego, California. · Department of Medicine, Providence St. Vincent Medical Center, Portland, Oregon. · Department of Medicine, St. Joseph's Hospital and Medical Center, Phoenix, Arizona. · Department of Medicine, INTEGRIS Baptist Medical Center, Oklahoma City, Oklahoma. · Department of Medicine, Geisinger Holy Spirit, Harrisburg, Pennsylvania. · Department of Medicine, Sanford Health, Sioux Falls, South Dakota. · Department of Medicine, Seton Heart Institute, Austin, Texas. · Department of Medicine, Arkansas Heart Hospital, Little Rock, Arkansas. · Department of Medicine, Cleveland Clinic, Cleveland, Ohio. ·JACC Cardiovasc Interv · Pubmed #29216997.

ABSTRACT: Significant progress has been made in the percutaneous coronary intervention technique from the days of balloon angioplasty to modern-day metallic drug-eluting stents (DES). Although metallic stents solve a temporary problem of acute recoil following balloon angioplasty, they leave behind a permanent problem implicated in very late events (in addition to neoatherosclerosis). BRS were developed as a potential solution to this permanent problem, but the promise of these devices has been tempered by clinical trials showing increased risk of safety outcomes, both early and late. This is not too dissimilar to the challenges seen with first-generation DES in which refinement of deployment technique, prolongation of dual antiplatelet therapy, and technical iteration mitigated excess risk of very late stent thrombosis, making DES the treatment of choice for coronary artery disease. This white paper discusses the factors potentially implicated in the excess risks, including the scaffold consideration and deployment technique, and outlines patient and lesion selection, implantation technique, and dual antiplatelet therapy considerations to potentially mitigate this excess risk with the first-generation thick strut Absorb scaffold (Abbott Vascular, Abbott Park, Illinois). It remains to be seen whether these considerations together with technical iterations will ultimately close the gap between scaffolds and metal stents for short-term events while at the same time preserving options for future revascularization once the scaffold bioresorbs.

11 Review Heartbeat: Glycaemic control and excess risk of major coronary events in type 1 diabetes. 2017

Rahimi, Kazem / Otto, Catherine M. ·George Institute, University of Oxford, Oxford, UK. · Division of Cardiology, University of Washington, Seattle, Washington, USA. ·Heart · Pubmed #29025920.

ABSTRACT: -- No abstract --

12 Review Multivessel Revascularization in Shock and High-Risk Percutaneous Coronary Intervention. 2017

Krishnan, Sandeep K / Riley, Robert F / Hira, Ravi S / Lombardi, William L. ·Division of Cardiology, University of Washington, School of Medicine, 1959 Northeast Pacific Street, Seattle, WA 98195, USA. · Division of Cardiology, University of Washington, School of Medicine, 1959 Northeast Pacific Street, Seattle, WA 98195, USA. Electronic address: lombaw@cardiology.washington.edu. ·Interv Cardiol Clin · Pubmed #28600093.

ABSTRACT: This review explores the usefulness of multivessel revascularization with percutaneous coronary intervention in patients with multivessel obstructive coronary artery disease (CAD) presenting with and without cardiogenic shock. We also evaluate the literature regarding complete versus incomplete revascularization for patients with cardiogenic shock, acute coronary syndromes, and stable coronary artery disease.

13 Review Update on the Management of Chronic Total Occlusions in Coronary Artery Disease. 2017

Kearney, Kathleen / Hira, Ravi S / Riley, Robert F / Kalyanasundaram, Arun / Lombardi, William L. ·Division of Cardiology, University of Washington, Seattle, WA, USA. KaKearney@cardiology.washington.edu. · Division of Cardiology, University of Washington, Seattle, WA, USA. · Division of Cardiology, Swedish Medical Center, Seattle, WA, USA. ·Curr Atheroscler Rep · Pubmed #28315181.

ABSTRACT: PURPOSE OF THE REVIEW: Chronic total occlusions (CTOs) are found in about a third of patients with coronary artery disease (CAD) and can pose a significant challenge during percutaneous revascularization. However, advances in CTO percutaneous coronary intervention (PCI) strategies, devices, and algorithms have led to significant improvements in successful treatment of CTOs. This review summarizes current management of CTOs in the context of modern PCI techniques and current evidence. RECENT FINDINGS: The hybrid algorithm now provides a standardized, teachable approach to CTO PCI, and success rates are approximately 90% in experienced hands. The first randomized controlled trial in patients with CTOs recently reported that patients with ST elevation myocardial infarction (STEMI) and a CTO in the non-culprit vessel showed an improvement in ejection fraction in patients undergoing CTO PCI of the LAD, but not other vessels. Updated data from the SYNTAX trial showed a benefit with complete revascularization in patients with coronary artery disease (CAD). Incomplete revascularization of CTOs in the PCI group may explain some of the benefit seen with CABG over PCI in patients with complex coronary disease. Contemporary CTO registries have reported success rates of approximately 90%, and the OPEN-CTO registry updates our understanding of CTO PCI complication rates and outcomes. The available evidence highlights the potential benefits of CTO PCI in patients with an indication for revascularization. Technological advancements have paved the way for success rates approaching 90% at high-volume centers, but further studies evaluating outcomes following CTO PCI are needed, with several currently underway.

14 Review Coronary artery perforation complicated by recurrent cardiac tamponade: a case illustration and review. 2017

DePersis, Michael / Khan, Safi U / Kaluski, Edo / Lombardi, William. ·Guthrie Clinic/Robert Packer Hospital, Sayre, PA 18840. Electronic address: Depersis_michael@guthrie.org. · Guthrie Clinic/Robert Packer Hospital, Sayre, PA 18840. · University of Washington, Seattle, WA 98195. ·Cardiovasc Revasc Med · Pubmed #28302464.

ABSTRACT: Coronary artery perforation during percutaneous intervention is a rare but potentially life threatening complication. The treatment of coronary perforation can be challenging in view of potential life threatening consequences such as cardiac tamponade or myocardial infarction. Presented is a clinical course of a 69year-old female who developed cardiac tamponade as a result of presumed wire related perforation of the posterolateral branch of the right coronary artery. Her clinical course was further complicated by recurrent tamponade, atrial fibrillation, stress induced cardiomyopathy, heparin induced thrombocytopenia and cardiogenic pulmonary edema. Based on review of the medical literature a treatment algorithm for wire perforation is suggested.

15 Review Enhancing Cardiac PET by Motion Correction Techniques. 2017

Rubeaux, Mathieu / Doris, Mhairi K / Alessio, Adam / Slomka, Piotr J. ·Cedars-Sinai Medical Center, 8700 Beverly Blvd Taper A238, Los Angeles, CA, 90048, USA. · Centre for Cardiovascular Science, University of Edinburgh, 49 Little France Crescent, Edinburgh EH16 4SB, Scotland, UK. · Department of Radiology, University of Washington, Old Fisheries Center, Room 222, 4000 15th Avenue NE, Box 357987, Seattle, WA, 98195-7987, USA. · Cedars-Sinai Medical Center, 8700 Beverly Blvd Taper A238, Los Angeles, CA, 90048, USA. piotr.slomka@cshs.org. · David Geffen School of Medicine, University of California, Los Angeles, CA, USA. piotr.slomka@cshs.org. · Cedars-Sinai Medical Center, 8700 Beverly Blvd Ste. A047N, Los Angeles, CA, 90048, USA. piotr.slomka@cshs.org. ·Curr Cardiol Rep · Pubmed #28185169.

ABSTRACT: PURPOSE OF REVIEW: Cardiac positron emission tomography (PET) images often contain errors due to cardiac, respiratory, and patient motion during relatively long image acquisition. Advanced motion compensation techniques may improve PET spatial resolution, eliminate potential artifacts, and ultimately improve the research and clinical capabilities of PET. RECENT FINDINGS: Combined cardiac and respiratory gating has only recently been implemented in clinical PET systems. Considering that the gated image bins contain much lower counts than the original PET data, they need to be summed after correcting for motion, forming motion-corrected, high-count image volume. Furthermore, automated image registration techniques can be used to correct for motion between CT attenuation scan and PET acquisition. While motion correction methods are not yet widely used in clinical practice, approaches including dual-gated non-rigid motion correction and the incorporation of motion correction information into the reconstruction process have the potential to markedly improve cardiac PET imaging.

16 Review Providing Evidence for Subclinical CVD in Risk Assessment. 2016

Blaha, Michael J / Yeboah, Joseph / Al Rifai, Mahmoud / Liu, Kiang / Kronmal, Richard / Greenland, Philip. ·Johns Hopkins Ciccarone Center for Prevention of Heart Disease, Baltimore, MD, USA. Electronic address: mblaha1@jhmi.edu. · Department of Internal Medicine/Cardiology, Wake Forest University Health Sciences, Winston Salem, NC, USA. · Departments of Preventive Medicine and Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. · Department of Biostatistics, University of Washington School of Public Health, Seattle, WA, USA. ·Glob Heart · Pubmed #27741975.

ABSTRACT: When the MESA (Multi-Ethnic Study of Atherosclerosis) began, the Framingham risk score was the preferred tool for 10-year global coronary heart disease risk assessment; however, the Framingham risk score had limitations including derivation in a homogenous population lacking racial and ethnic diversity and exclusive reliance on traditional risk factors without consideration of most subclinical disease measures. MESA was designed to study the prognostic value of subclinical atherosclerosis and other risk markers in a multiethnic population. In a series of landmark publications, MESA demonstrated that measures of subclinical cardiovascular disease add significant prognostic value to the traditional Framingham risk variables. In head-to-head studies comparing these markers, MESA established that the coronary artery calcium score may be the single best predictor of coronary heart disease risk. Results from MESA have directly influenced recent prevention guidelines including the recommendations on risk assessment and cholesterol-lowering therapy. The MESA study has published its own risk score, which allows for the calculation of 10-year risk of coronary heart disease before and after knowledge of a coronary artery calcium score.

17 Review PROMISE of Coronary CT Angiography: Precise and Accurate Diagnosis and Prognosis in Coronary Artery Disease. 2016

Thomas, Dustin M / Branch, Kelley R / Cury, Ricardo C. ·From the Cardiology Division, Brooke Army Medical Center, San Antonio, Texas, the Cardiology Division, University of Washington, Seattle, and the Miami Cardiac and Vascular Institute, Baptist Health of South Florida, Miami. ·South Med J · Pubmed #27043808.

ABSTRACT: Coronary computed tomography angiography (CCTA) is a rapidly growing and powerful diagnostic test that offers a great deal of precision with respect to diagnosing coronary artery disease (CAD). Guideline statements for patients with stable ischemic heart disease have recommended CCTA for only a limited portion of intermediate-risk patients who have relative or absolute contraindications for exercise or vasodilator stress testing. The publication of two large, prospective randomized clinical trials, the Prospective Multicenter Imaging Study for Evaluation of Chest Pain and the Scottish Computed Tomography of the Heart Trial are likely to expand these indications. These new data from large trials, in addition to other studies, show that CCTA is highly sensitive for the detection of CAD, identifies high-risk patients for cardiac events based on extent or plaque morphology of CAD that would not be identified by other noninvasive means, and provides significantly greater diagnostic certainty for proper treatment, including referral for invasive coronary angiography with revascularization more appropriately. Superior diagnostic accuracy and prognostic data with CCTA, when compared with other functional stress tests, may result in a reduction in unnecessary downstream testing and cost savings. In addition, newer CCTA applications hold the promise of providing a complete evaluation of a patient's coronary anatomy as well as a per-vessel ischemic evaluation. This review focuses on the interval knowledge obtained from newer data on CCTA in patients with stable ischemic heart disease, primarily focusing on the contributions of the Prospective Multicenter Imaging Study for Evaluation of Chest Pain and the Scottish Computed Tomography of the Heart Trial.

18 Review Clinical Inquiry: Is lower BP worth it in higher-risk patients with diabetes or coronary disease? 2016

Kelsberg, Gary / Russell, Telly / Safranek, Sarah. ·University of Washington at Valley Family Medicine Residency, Renton, WA, USA. · University of Washington Health Sciences Library, Seattle, WA, USA. ·J Fam Pract · Pubmed #26977465.

ABSTRACT: There is no simple answer; the risk/benefit picture is complicated. Controlling blood pressure to a target of 130/80 mm Hg or lower produces mixed results in patients with diabetes and coronary disease equivalents.

19 Review Coronary computed tomography angiography and its increasing application in day to day cardiology practice. 2016

Markham, R / Murdoch, D / Walters, D L / Hamilton-Craig, C. ·Heart and Lung Institute, The Prince Charles Hospital, Brisbane, Australia. · University of Queensland, Brisbane, Australia. · University of Washington, Seattle, Washington, USA. ·Intern Med J · Pubmed #26813899.

ABSTRACT: Coronary artery disease (CAD) is the leading single cause of death in Australia affecting around 1.4 million people. Coronary computed tomography angiography has an established role in the assessment of patients with low to intermediate pretest probability for CAD who have chest pain and is typically used with the aim to rule out significant coronary artery stenosis. Use was initially limited because of concerns over radiation exposure, a Medicare rebate restricted to specialist referrals and an absence of data supporting its use as an alternative to functional testing in patients with chest pain. Recent advances in scanner technology and image sequencing, along with data from randomised control trials, have addressed these issues and indicate that coronary computed tomography angiography will play a greater role in the assessment of CAD in the coming years.

20 Review ISPD Cardiovascular and Metabolic Guidelines in Adult Peritoneal Dialysis Patients Part II - Management of Various Cardiovascular Complications. 2015

Wang, Angela Yee Moon / Brimble, K Scott / Brunier, Gillian / Holt, Stephen G / Jha, Vivekanand / Johnson, David W / Kang, Shin-Wook / Kooman, Jeroen P / Lambie, Mark / McIntyre, Chris / Mehrotra, Rajnish / Pecoits-Filho, Roberto. ·Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong aymwang@hkucc.hku.hk. · St. Joseph's Healthcare, McMaster University, Hamilton, Ontario, Canada. · Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, Ontario, Canada. · Division of Nephrology, The Royal Melbourne Hospital, University of Melbourne, Melbourne, Australia. · George Institute for Global Health India, Postgraduate Institute of Medical Education and Research, Chandigarh, India. · University of Queensland at Princess Alexandra Hospital, Brisbane, Australia Centre for Kidney Disease Research, Translational Research Institute, Brisbane, Australia. · Department of Internal Medicine, College of Medicine, Severance Biomedical Science Institute, Yonsei University, Korea. · Division of Nephrology, University Hospital Maastricht, Maastricht, The Netherlands. · Health Services Research Unit, Institute for Science and Technology in Medicine, Keele University, Keele, Staffordshire, United Kingdom. · School of Medicine, University of Nottingham, Royal Derby Hospital Centre, Derby, United Kingdom. · Harborview Medical Center, Division of Nephrology/Department of Medicine, University of Washington, Washington, DC, United States. · School of Medicine, Pontifícia Universidade Católica do Paraná, Curitiba, Paraná, Brazil. ·Perit Dial Int · Pubmed #26228783.

ABSTRACT: Cardiovascular mortality has remained high in patients on peritoneal dialysis (PD) due to the high prevalence of various cardiovascular complications including coronary artery disease, left ventricular hypertrophy and dysfunction, heart failure, arrhythmia (especially atrial fibrillation), cerebrovascular disease, and peripheral arterial disease. In addition, nearly a quarter of PD patients develop sudden cardiac death as the terminal life event. Thus, it is essential to identify effective treatment that may lower cardiovascular mortality and improve survival of PD patients. The International Society for Peritoneal Dialysis (ISPD) commissioned a global workgroup in 2012 to formulate a series of recommendation statements regarding lifestyle modification, assessment and management of various cardiovascular risk factors, and management of the various cardiovascular complications to be published in 2 guideline documents. This publication forms the second part of the guideline documents and includes recommendation statements on the management of various cardiovascular complications in adult chronic PD patients. The documents are intended to serve as a global clinical practice guideline for clinicians who look after PD patients. We also define areas where evidence is clearly deficient and make suggestions for future research in each specific area.

21 Review Nutritional factors in the prevention and management of coronary artery disease and heart failure. 2015

Das, Undurti N. ·UND Life Sciences, Federal Way, WA, USA and Department of Medicine and BioScience Research Centre, Gayatri Vidya Parishad Hospital, Campus of GVP College of Engineering, Visakhapatnam, India. Electronic address: undurti@hotmail.com. ·Nutrition · Pubmed #25592005.

ABSTRACT: Nutritional factors such as magnesium, folic acid, vitamins B12 and B6, L-arginine, and polyunsaturated fatty acids (PUFAs) appear to be significantly beneficial for patients with coronary artery disease (CAD), and in the prevention and arresting the progression of HF and cardiac arrhythmias. Additionally, ingestion of adequate amounts of protein and maintaining normal concentrations of plasma albumin seem to be essential for these patients. These nutrients closely interact with the metabolism of L-arginine-nitric oxide (NO) system, essential fatty acids, and eicosanoids such that beneficial products such as NO, prostaglandin E1, prostacyclin, prostaglandin I3, lipoxins, resolvins, and protectins are generated and synthesis of proinflammatory cytokines is suppressed that results in platelet anti-aggregation, vasodilation, angiogenesis, and prevention of CAD, cardiac arrhythmias, and stabilization of HF. This implies that individuals at high risk for CAD, cardiac arrhythmias, and HF and those who have these diseases need to be screened for plasma levels of magnesium, folic acid, vitamins B12 and B6, L-arginine, NO, various PUFAs, lipoxin A4, resolvins, protectins, asymmetrical dimethylarginine (an endogenous inhibitor of NO), albumin, and various eicosanoids and cytokines and correct their abnormalities to restore normal physiology.

22 Review The effect of hepatic lipase on coronary artery disease in humans is influenced by the underlying lipoprotein phenotype. 2012

Brunzell, John D / Zambon, Alberto / Deeb, Samir S. ·University of Washington, Department of Medicine, Division of Metabolism, Endocrinology and Nutrition, Box 356426, 1959 NE Pacific Avenue, Seattle, Washington 98195, USA. brunzell@uw.edu ·Biochim Biophys Acta · Pubmed #21986251.

ABSTRACT: Increased or decreased hepatic lipase (HL) activity has been associated with coronary artery disease (CAD). This is consistent with the findings that gene variants that influence HL activity were associated with increased CAD risk in some population studies but not in others. In this review, we will explain the conditions that influence the effects of HL on CAD. Increased HL is associated with smaller and denser LDL (sdLDL) and HDL (HDL(3)) particles, while decreased HL is associated with larger and more buoyant LDL and HDL particles. The effect of HL activity on CAD risk is dependent on the underlying lipoprotein phenotype or disorder. Central obesity with hypertriglyceridemia (HTG) is associated with high HL activity that leads to the formation of sdLDL that is pro-atherogenic. In the absence of HTG, where large buoyant cholesteryl ester-enriched LDL is prominent, elevation of HL does not raise the risk for CAD. In HTG patients, drug therapy that decreases HL activity selectively decreases sdLDL particles, an anti-atherogenic effect. Drug therapy that raises HDL(2) cholesterol has not decreased the risk for CAD. In trials where inhibition of cholesterol ester transfer protein (CETP) or HL occurs, the increase in HDL(2) most likely is due to inhibition of catabolism of HDL(2) and impairment of reverse cholesterol transport (RCT). In patients with isolated hypercholesterolemia, but with normal triglyceride levels and big-buoyant LDL particles, an increase in HL activity is beneficial; possibly because it increases RCT. Drugs that lower HL activity might decrease the risk for CAD only in hypertriglyceridemic patients with sdLDL by selectively clearing sdLDL particles from plasma, which would override the potentially pro-atherogenic effect on RCT. This article is part of a Special Issue entitled Advances in High Density Lipoprotein Formation and Metabolism: A Tribute to John F. Oram (1945-2010).

23 Review Insulin resistance, hyperglycemia, and atherosclerosis. 2011

Bornfeldt, Karin E / Tabas, Ira. ·Department of Pathology, Diabetes and Obesity Center of Excellence, 815 Mercer Street, University of Washington, Seattle, WA 98109, USA. ·Cell Metab · Pubmed #22055501.

ABSTRACT: Progress in preventing atherosclerotic coronary artery disease (CAD) has been stalled by the epidemic of type 2 diabetes. Further advances in this area demand a thorough understanding of how two major features of type 2 diabetes, insulin resistance and hyperglycemia, impact atherosclerosis. Insulin resistance is associated with systemic CAD risk factors, but increasing evidence suggests that defective insulin signaling in atherosclerotic lesional cells also plays an important role. The role of hyperglycemia in CAD associated with type 2 diabetes is less clear. Understanding the mechanisms whereby type 2 diabetes exacerbates CAD offers hope for new therapeutic strategies to prevent and treat atherosclerotic vascular disease.

24 Review Clinical Inquiries: What is the best noninvasive diagnostic test for women with suspected CAD? 2010

Starr, Hillary / Powers, Laurel / Safranek, Sarah. ·University of Washington Department of Family Medicine, Tacoma Family Medicine Residency Program, Tacoma, WA, USA. ·J Fam Pract · Pubmed #20824233.

ABSTRACT: Multidetector computed tomography (MDCT) may be the most sensitive and specific noninvasive diagnostic test for women with suspected coronary artery disease (CAD) (strength of recommendation [SOR]: A, multiple prospective cohort studies). However, stress echocardiography and nuclear medicine perfusion testing are still the best well-tested and readily available alternatives in light of the newness of MDCT and concerns regarding its use (SOR: A, meta-analysis and cohort studies). Standard exercise treadmill testing (ETT) doesn't adequately exclude or confirm CAD in women (SOR: A, multiple prospective cohort studies).

25 Review Type 2 diabetes mellitus and the risk of sudden cardiac arrest in the community. 2010

Siscovick, David S / Sotoodehnia, Nona / Rea, Thomas D / Raghunathan, Trivellore E / Jouven, Xavier / Lemaitre, Rozenn N. ·Medicine and Epidemiology, University of Washington, Cardiovascular Health Research Unit, 1730 Minor Avenue, Seattle, WA 98101, USA. dsisk@u.washington.edu ·Rev Endocr Metab Disord · Pubmed #20195771.

ABSTRACT: The reduction of mortality from sudden cardiac arrest (SCA) in the setting of coronary heart disease (CHD) remains a major challenge, especially among patients with type 2 diabetes. Diabetes is associated with an increased risk of SCA, at least in part, from an increased presence and extent of coronary atherosclerosis (macrovascular disease). Diabetes also is associated with microvascular disease and autonomic neuropathy; and, these non-coronary atherosclerotic pathophysiologic processes also have the potential to increase the risk of SCA. In this report, we review the absolute and relative risk of SCA associated with diabetes. We summarize recent evidence that suggests that the increase in risk in patients with diabetes is not specific for SCA, as diabetes also is associated with a similar increase in risk for non-SCA CHD death and non-fatal myocardial infarction. These data are consistent with prior observations that coronary atherosclerosis is a major contributor to the increased SCA risk associated with diabetes. We also present previously published and unpublished data that demonstrates that both clinically-recognized microvascular and autonomic neuropathy also are associated with the risk of SCA among treated patients with diabetes, after taking into account prior clinically-recognized heart disease and other risk factors for SCA. We then discuss how these data might inform research and clinical efforts to prevent SCA. Although the prediction of SCA in this "high" risk population is likely to remain a challenge, as it is in other "high" risk clinical populations, we suggest that current recommendations for the prevention of SCA in the community, related to both lifestyle prescriptions and risk factor reduction, are likely to reduce mortality from SCA among patients with diabetes.

Next